Current issues on resistance, treatment guidelines, and the appropriate use of fluoroquinolones for respiratory tract infections

Clinical Therapeutics

Volumn 24, Issue 6, 2002, Pages 838-850

  Bishai, William ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Antimicrobial resistance; Appropriate use; Bronchitis; Fluoroquinolone; Guidelines; Pneumonia; Respiratory tract infections; Sinusitis; Streptococcus pneumoniae

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BRONCHITIS; DISEASE SEVERITY; DRUG ACTIVITY; HOSPITALIZATION; HUMAN; MEDLINE; PNEUMONIA; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; COMMUNICABLE DISEASE; DRUG RESISTANCE; ECONOMICS;

ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE; FLUOROQUINOLONES; HUMANS; PRACTICE GUIDELINES; RESPIRATORY TRACT INFECTIONS;

EID: 0036302152     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80002-9     Document Type: Article

References (31)

1. Drug resistance and the treatment of upper respiratory infections
2. Get a handle on resistance before it gets a handle on you: The PROTEKT US Surveillance Study. Prospective Resistant Organism Tracking and Epidemiology for Ketolide Telithromycin
3. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program
4. A focus on acute sinusitis in adults: Changes in disease management
5. Community-acquired pneumonia: Epidemiology, etiology, treatment
6. Resistance of Streptococcus pneumoniae to fluoroquinolones - United States, 1995-1999
7. Update: Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis
8. Anthrax as a biological weapon: Updated recommendations for management
9. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
10. Fluoroquinolone resistance in Streptococcus pneumoniae
11. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: Results of a Hong Kong multicentre study in 2000
12. The in vivo-in vitro paradox in pneumococcal respiratory tract infections
13. Emerging mechanisms of fluoroquinolone resistance
14. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States
15. Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States
16. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections
17. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
18. Practice guidelines for the management of community-acquired pneumonia in adults
19. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention
20. A prediction rule to identify low-risk patients with community-acquired pneumonia
21. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Sinus and Allergy Health Partnership
22. A nosocomial outbreak of fluoroquinolone-resistant salmonella infection
23. Clinical choices of antibiotics: Judging judicious use
24. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates
25. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I
26. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
27. Impact of the introduction of pneumococcal conjugate vaccine on the epidemiology of invasive pneumococcal disease in children less than five years of age within Northern California Kaiser Permanente (NCKP)
28. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine
29. Nasopharyngeal carriage of antimicrobial-resistant Streptococcus pneumoniae among young children attending 79 kindergartens and day care centers in Hong Kong
30. Macrolide resistance among invasive Streptococcus pneumoniae isolates
31. Pneumococcal polysaccharide vaccine